
|Videos|October 20, 2021
AMCP Nexus 2021: Cate Lockhart of Biologics and Biosimilars Collective Intelligence Consortium Discusses Biosimilars Such as Semglee and the Current Standing of Biosimilars, PBMs
Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
4
Venclexta combination improves survival and lowers hospital stays for AML patients | ASH 2025
5





















































